Compare Merck & Co., Inc. (MRK) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Financial Select Sector SPDR Fund — how do they compare? Merck & Co., Inc. trades at $133.82 (market cap $327.94B), while Financial Select Sector SPDR Fund trades at $58.09. The key difference: Merck & Co., Inc. pays a 2.56% dividend while Financial Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| MRK | XLF | |
|---|---|---|
Market Cap | $327.94B | — |
Sector | Health | — |
52-Week High | $132.93 | $58.01 |
52-Week Low | $77.60 | $47.80 |
Enterprise Value | $374.70B | — |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $133.30, up 2.18% today, with a bullish technical signal and strong institutional buying interest. Recent earnings beats and the acquisition of Terns Pharmaceuticals for $6.7 billion highlight strategic growth in oncology. The stock shows robust cash flow from operations of $16.47 billion in 2025 and a consensus price target of $140.58, indicating potential upside.
Outlook remains positive with analyst consensus at 67.57% buy ratings, though risks include high P/E of 106.34 and net income margin volatility. The acquisition expands Merck's pipeline but integration execution is key. Dividend yield supports income investors, while valuation metrics suggest careful monitoring of earnings growth sustainability.
XLF, the Financial Select Sector SPDR ETF, trades at $57.91, up 0.17% today, with a bullish technical signal driven by moving averages. Recent news highlights record inflows into sector ETFs and strong Q2 bank earnings, while technical indicators show overbought RSI levels. The ETF crossed above its 200-day moving average, signaling positive momentum.
The outlook for XLF is positive due to sector strength and AI-driven financial opportunities, but risks include market volatility and high expectations. Investors benefit from diversification and a dividend yield, though overbought conditions suggest potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
